Published in Climacteric on June 01, 2012
Acupuncture for menopausal vasomotor symptoms: study protocol for a randomised controlled trial. Trials (2014) 1.41
On the role of skin in the regulation of local and systemic steroidogenic activities. Steroids (2015) 1.01
An update on the cognitive impact of clinically-used hormone therapies in the female rat: models, mazes, and mechanisms. Brain Res (2013) 0.89
Estrogen receptors, the hippocampus, and memory. Neuroscientist (2014) 0.88
The ocular benefits of estrogen replacement therapy: a population-based study in postmenopausal Korean women. PLoS One (2014) 0.84
From the 90׳s to now: A brief historical perspective on more than two decades of estrogen neuroprotection. Brain Res (2015) 0.83
PuF, an antimetastatic and developmental signaling protein, interacts with the Alzheimer's amyloid-β precursor protein via a tissue-specific proximal regulatory element (PRE). BMC Genomics (2013) 0.82
Oestradiol modulation of cognition in adult female marmosets (Callithrix jacchus). J Neuroendocrinol (2014) 0.81
ω-3 fatty acids and domain-specific cognitive aging: secondary analyses of data from WHISCA. Neurology (2013) 0.79
Short-term testosterone manipulations do not affect cognition or motor function but differentially modulate emotions in young and older male rhesus monkeys. Horm Behav (2014) 0.78
Utilizing induced pluripotent stem cells (iPSCs) to understand the actions of estrogens in human neurons. Horm Behav (2015) 0.77
Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci (2016) 0.76
The pregnane xenobiotic receptor, a prominent liver factor, has actions in the midbrain for neurosteroid synthesis and behavioral/neural plasticity of female rats. Front Syst Neurosci (2014) 0.76
A comparative evaluation of treatments with 17β-estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer's disease. Horm Behav (2016) 0.75
Reprint of: From the 90׳s to now: A brief historical perspective on more than two decades of estrogen neuroprotection. Brain Res (2016) 0.75
Luteinizing hormone downregulation but not estrogen replacement improves ovariectomy-associated cognition and spine density loss independently of treatment onset timing. Horm Behav (2015) 0.75
Progestogens' effects and mechanisms for object recognition memory across the lifespan. Behav Brain Res (2015) 0.75
Impact of Sex and Menopausal Status on Episodic Memory Circuitry in Early Midlife. J Neurosci (2016) 0.75
Menopausal Hormone Therapy, Age, and Chronic Diseases: Perspectives on Statistical Trends. Chem Res Toxicol (2016) 0.75
Differences in the lipid profile and hormone replacement therapy use in Korean postmenopausal women: the Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012. Arch Gynecol Obstet (2015) 0.75
Estrogenic Endocrine Disrupting Chemicals Influencing NRF1 Regulated Gene Networks in the Development of Complex Human Brain Diseases. Int J Mol Sci (2016) 0.75
Oxabicycloheptene Sulfonate Protects Against β-Amyloid-induced Toxicity by Activation of PI3K/Akt and ERK Signaling Pathways Via GPER1 in C6 Cells. Neurochem Res (2017) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology (2007) 12.42
Mild cognitive impairment. Lancet (2006) 10.21
Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet (1996) 7.10
Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA (2002) 6.72
Survival after initial diagnosis of Alzheimer disease. Ann Intern Med (2004) 5.52
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA (2000) 3.99
Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology (1999) 3.95
Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology (2000) 3.89
Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA (2004) 3.85
Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology (2000) 3.39
Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology (2005) 2.45
Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology (2009) 2.45
The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort. Arch Neurol (1995) 2.42
Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA (2001) 2.32
Hormone therapy and risk of Alzheimer disease: a critical time. JAMA (2002) 2.16
Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology (1992) 2.05
Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab (2006) 2.03
Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med (2002) 2.02
Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology (1988) 1.99
Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. J Neurosci (2006) 1.95
Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med (2001) 1.87
The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology (1997) 1.70
Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol (2011) 1.63
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry (2005) 1.62
Dementia and Alzheimer disease incidence rates do not vary by sex in Rochester, Minn. Arch Neurol (2002) 1.58
Incidence of dementia and Alzheimer's disease: a reanalysis of data from Rochester, Minnesota, 1975-1984. Am J Epidemiol (1998) 1.57
Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med (1996) 1.57
Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol (2009) 1.54
The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. Clin Trials (2004) 1.52
Raloxifene improves verbal memory in late postmenopausal women: a randomized, double-blind, placebo-controlled trial. Menopause (2010) 1.45
Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry (2005) 1.45
Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol (2010) 1.44
Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology (2007) 1.43
The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience (2000) 1.41
Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience (2005) 1.38
Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. Neurology (2009) 1.32
Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology (2000) 1.29
Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci (2005) 1.27
Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users and men: a possible window of opportunity effect. Neurobiol Aging (2006) 1.27
A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. Neurobiol Aging (2005) 1.24
Hormone therapy and cognitive function. Hum Reprod Update (2009) 1.22
Enrollment in a brain magnetic resonance study: results from the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study (WHIMS-MRI). Acad Radiol (2007) 1.22
Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J Clin Endocrinol Metab (2009) 1.13
Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life. Arch Neurol (2006) 1.10
Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology (1996) 1.05
Brain volumes, cognitive impairment, and conjugated equine estrogens. J Gerontol A Biol Sci Med Sci (2009) 1.05
Cognitive deficits of men and women with Alzheimer's disease. Neurology (1994) 1.02
Gender differences in language of AD patients: a longitudinal study. Neurology (1995) 1.02
Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). Am J Obstet Gynecol (2005) 1.00
Clinically relevant progestins regulate neurogenic and neuroprotective responses in vitro and in vivo. Endocrinology (2010) 0.95
Effects of botanicals and combined hormone therapy on cognition in postmenopausal women. Menopause (2009) 0.94
The effect of 3-year treatment with 0.25 mg/day of micronized 17beta-estradiol on cognitive function in older postmenopausal women. J Am Geriatr Soc (2007) 0.91
Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Psychoneuroendocrinology (1996) 0.91
Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J Womens Health (Larchmt) (2010) 0.88
Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males. Neuropsychopharmacology (2005) 0.88
Raloxifene affects brain activation patterns in postmenopausal women during visual encoding. J Clin Endocrinol Metab (2001) 0.87
Subtypes of mild cognitive impairment in older postmenopausal women: the Women's Health Initiative Memory Study. Alzheimer Dis Assoc Disord (2010) 0.84
Impact of clinically relevant progestins on the neural effects of estradiol and the signaling pathways involved. Drug News Perspect (2005) 0.79
Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology (1981) 3.47
The practice of neurology, 2000-2010: report of the AAN Member Research Subcommittee. Neurology (2011) 2.59
Boston Naming Test: shortened versions for use in Alzheimer's disease. J Gerontol (1992) 2.23
Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol (1994) 2.14
Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric (2013) 1.94
Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med (1996) 1.57
Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric (2011) 1.47
In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry (2000) 1.41
Age of menopause and impact of climacteric symptoms by geographical region. Climacteric (2010) 1.35
Clock drawing: analysis in a retirement community. J Am Geriatr Soc (2001) 1.31
Clinical subtypes of dementia of the Alzheimer type. Neurology (1985) 1.23
Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis Assoc Disord (2000) 1.21
Boston Naming Test in Alzheimer's disease. Neuropsychologia (1989) 1.15
Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology (1996) 1.05
Anatomy of posterior pathways in reading: a reassessment. Brain Lang (1986) 1.00
Prevention of diseases after menopause. Climacteric (2014) 0.99
Occupations with exposure to electromagnetic fields: a possible risk factor for Alzheimer's disease. Am J Epidemiol (1995) 0.98
Assessing working memory and language comprehension in Alzheimer's disease. Brain Lang (2001) 0.98
The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD Study. Consortium to Establish a Registry for Alzheimer's Disease. Neurology (1997) 0.96
Gender differences on a brief measure of cognitive functioning in Alzheimer's disease. Arch Neurol (1993) 0.94
Associations between circulating sex steroid hormones and cognition in normal elderly women. Neurology (2000) 0.93
The consortium to establish a registry for Alzheimer's Disease (CERAD). Part XIII. Obtaining autopsy in Alzheimer's disease. Neurology (1996) 0.93
Speech fluency in crossed aphasia. Brain (1983) 0.92
Anosognosia and Alzheimer's disease: the role of depressive symptoms in mediating impaired insight. J Clin Exp Neuropsychol (2000) 0.90
Gender comparisons of cognitive performances among vascular dementia, Alzheimer disease, and older adults without dementia. Arch Neurol (1996) 0.86
Concurrent validity of Spanish-language versions of the Mini-Mental State Examination, Mental Status Questionnaire, Information-Memory-Concentration test, and Orientation-Memory-Concentration test: Alzheimer's disease patients and nondemented elderly comparison subjects. J Int Neuropsychol Soc (1996) 0.83
P300 topography in Alzheimer's disease. Psychophysiology (1995) 0.82
The effects of hormone replacement therapy, lipoprotein cholesterol levels, and other factors on a clock drawing task in older women. J Am Geriatr Soc (1996) 0.82
Severity of dementia in Alzheimer disease and neurofibrillary tangles in multiple brain regions. Alzheimer Dis Assoc Disord (1991) 0.81
Right thalamic injury, impaired visuospatial perception, and alexia. Neurology (1982) 0.81
Left hemisphere pathways in reading: inferences from pure alexia without hemianopia. Neurology (1985) 0.79
Jules Dejerine and the third alexia. Arch Neurol (1984) 0.78
Detecting dementia in just 12 minutes: the seven minute screen. J Neurol Neurosurg Psychiatry (2004) 0.78
Body weight, estrogen and cognitive functioning in Alzheimer's disease: an analysis of the Tacrine Study Group data. Arch Gerontol Geriatr (2004) 0.78
Estrogen in the treatment and prevention of Alzheimer's disease. Int J Pharm Compd (2013) 0.75
Spouses of demented patients with low cobalamin levels: a new risk group for cobalamin deficiency. Eur J Haematol (1996) 0.75
Does estrogen therapy enhance memory? Climacteric (1999) 0.75
CT criteria of hemisphere asymmetry fail to predict language laterality. Neurology (1984) 0.75
Monoclonal antibodies react with neuronal subpopulations in the human nervous system. J Comp Neurol (1988) 0.75
Paul Broca's less heralded contributions to aphasia research. Historical perspective and contemporary relevance. Arch Neurol (1986) 0.75
Questions about dantrolene for neuroleptic malignant syndrome. Am J Psychiatry (1983) 0.75
Neuromagnetic localization using magnetic resonance images. IEEE Trans Med Imaging (1992) 0.75
Lesion localization in Broca's aphasia. Implications from Broca's aphasia without hemiparesis. Arch Neurol (1985) 0.75
Impaired hue discrimination in homonymous visual fields. Arch Neurol (1982) 0.75
Lipomas of the mesencephalic tectum and rostral pons associated with sleep apnea syndrome. Clin Neuropathol (1990) 0.75